ReviewActa pharmacologica Sinica2020
Advanced biomaterials for cancer immunotherapy.
Review in Acta pharmacologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy.Immunologic research · 2026Review
- Drug Delivery Engineering Strategies Targeting CD4+/CD8+ T Cell Exhaustion to Improve the Tumor Immunosuppressive Microenvironment.International journal of nanomedicine · 2026Review
- Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Materials today. Bio · 2025Review
- Controlling Release Kinetics of an Adjuvant from a Depot Improves the Efficacy of Local Immunotherapy in Metastatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.Essays in biochemistry · 2025Review
- Extracellular Vesicles in Osteogenesis: A Comprehensive Review of Mechanisms and Therapeutic Potential for Bone Regeneration.Current issues in molecular biology · 2025Review
- Marine-Origin Polysaccharides and Their Chemically Modified Derivatives as Sources of Advanced Biofunctional Materials for Biomedical Applications.Biomacromolecules · 2025Review
- Study of PVP and PLA Systems and Fibers Obtained by Solution Blow Spinning for Chlorhexidine Release.Polymers · 2025Article
- Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Review
- Nano drug delivery systems for advanced immune checkpoint blockade therapy.Theranostics · 2025Review
- Micro- and Nanostructured Biomaterials for Biomedical Applications and Regenerative Medicine.Nanomaterials (Basel, Switzerland) · 2024Article
- Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.International journal of molecular sciences · 2024Review
- Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules · 2024Review
- Self-Assembly Study of Block Copolypeptoids in Response to pH and Temperature Stimulation.Polymers · 2024Article
- Recent Advancements in Biomaterials for Chimeric Antigen Receptor T Cell Immunotherapy.Biomaterials research · 2024Review
- Recent Progress of Bioinspired Cell Membrane in Cancer Immunotherapy.Clinical Medicine Insights. Oncology · 2024Review
- Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy.Bioactive materials · 2023Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy, as a powerful strategy for cancer treatment, has achieved tremendous efficacy in clinical trials. Despite these advancements, there is much to do in terms of enhancing therapeutic benefits and decreasing the side effects of cancer immunotherapy. Advanced nanobiomaterials, including liposomes, polymers, and silica, play a vital role in the codelivery of drugs and immunomodulators. These nanobiomaterial-based delivery systems could effectively promote antitumor immune responses and simultaneously reduce toxic adverse effects. Furthermore, nanobiomaterials may also combine with each other or with traditional drugs via different mechanisms, thus giving rise to more accurate and efficient tumor treatment. Here, an overview of the latest advancement in these nanobiomaterials used for cancer immunotherapy is given, describing outstanding systems, including lipid-based nanoparticles, polymer-based scaffolds or micelles, inorganic nanosystems, and others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.